ArticleAACE endocrinology and diabetes
Successful Treatment of Hypothalamic Obesity with Tirzepatide.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review.Current obesity reports · 2026Review
- Review
- Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.Frontiers in endocrinology · 2026Review
- Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes.Cureus · 2025Article
- Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life.Pituitary · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Hypothalamic obesity (HO) is a rare but severe form of obesity characterized by hypothalamic damage resulting in hyperphagia and decreased energy expenditure. Tumors involving the hypothalamus, most commonly craniopharyngiomas, frequently result in HO. Treatment is typically refractory to standard antiobesity treatment modalities. Herein, we describe a young man with HO due to surgical resection of a large craniopharyngioma who was successfully treated with tirzepatide, a novel treatment for obesity and type 2 diabetes. Case Report: A 21-year-old man presented with headaches for 7 months. His physical examination revealed a body weight of 125 kg (body mass index [BMI], 35 kg/m Discussion: The pathophysiology of HO is complex, involving decreased sympathetic activity and energy expenditure, central insulin and leptin resistance, and increased energy storage in adipose tissue. By modulating sympathetic/parasympathetic tone and regulating energy balance, tirzepatide appears to be a promising agent to address the complex pathophysiology of HO. Conclusion: This case report highlights the novel use of tirzepatide in the treatment of HO. This case informs clinicians of the potential benefits of considering tirzepatide in the management of HO and encourages further exploration of its use in this context.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.